The study, published in the journal Medical Oncology, was led by Saumyadeep Bora and Hitesh Kulhari of the School of Nano Sciences at the Central University of Gujarat, with collaborators from JSS Academy of Higher Education and Research, Parul University, and additional investigators at the Central University of Gujarat. The team set out to solve a problem that has shadowed cordycepin since its earliest characterization: the molecule, formally known as 3′-deoxyadenosine, is structurally almost identical to adenosine, the nucleoside that cells use constantly for energy transfer and signaling. That similarity makes cordycepin a prime target for adenosine deaminase, an abundant enzyme that chemically deaminates the compound and strips it of its anticancer activity within a short time of entering circulation.

The pharmacokinetic obstacles do not stop there. In the stomach, cordycepin encounters a strongly acidic environment that destabilizes the molecule before it can even be absorbed. Once absorbed, its poor pharmacokinetic profile means that little of an administered dose survives long enough or concentrates sufficiently in tumor tissue to do meaningful damage. Conventional cancer therapies suffer from a related cluster of problems, including low bioavailability, non-selective targeting of healthy tissues, and toxicity at the high doses often needed to achieve an effect. Rather than modifying cordycepin itself, the researchers chose to shield it, using a delivery technology that has matured steadily over the past two decades: solid lipid nanoparticles, or SLNs.

Solid lipid nanoparticles are spherical carriers typically tens to a few hundred nanometers across, built from lipids that remain solid at body temperature. A hydrophobic or amphiphilic drug can be dissolved in the molten lipid matrix during preparation, and as the lipid solidifies, the drug becomes entrapped within the particle core. Compared with polymeric nanoparticles, SLNs offer several practical advantages: they can be produced without organic solvents, they use biocompatible excipients, they protect labile molecules from enzymatic and chemical degradation, and they can sustain drug release over extended periods. Their lipid composition also encourages uptake by cell membranes, which are themselves lipid-rich, a property the researchers hoped to exploit to increase how much cordycepin actually gets inside cancer cells.

The team formulated cordycepin-loaded SLNs, abbreviated CSLN, and subjected them to a battery of characterization tests. The resulting particles were monodispersed, meaning they fell within a narrow, uniform size range, a critical property for reproducible drug delivery because particle size governs both circulation behavior and cellular uptake. Imaging and physical characterization confirmed that the particles were spherical and possessed good physical and chemical stability, indicating that the encapsulated drug would not prematurely leak or degrade during storage or transport. Uniform, stable, well-formed particles are the baseline requirement for any nanoformulation to move credibly toward preclinical evaluation, and the CSLN system appears to meet that baseline.

Release behavior was examined under two pH conditions designed to mimic different biological compartments. In acidic conditions, which correspond to the endo-lysosomal environment that nanoparticles encounter after being swallowed by cells, and at physiological pH, which corresponds to the pH of systemic circulation, the CSLN formulations exhibited sustained release of their cargo. This pH-responsive, prolonged release profile serves a dual purpose. In the bloodstream, slow release limits the burst exposure that drives off-target toxicity and rapid clearance. Inside the tumor cell’s acidic vesicles, release is retained, ensuring that the drug is liberated precisely where it can most effectively reach its intracellular targets rather than being lost in the extracellular environment.

The functional payoff of this engineering showed up clearly in cytotoxicity assays against MCF-7 cells, a widely used human breast cancer cell line. Compared with free cordycepin administered in its conventional soluble form, the CSLN formulation significantly enhanced the compound’s cytotoxic effect. The researchers attribute this improvement to two linked mechanisms. First, improved cellular uptake: nanoparticles are internalized by cells through endocytic pathways that free small molecules cannot use, allowing far greater quantities of the drug to accumulate inside the cell. Second, the sustained intracellular release keeps drug levels high at the relevant sites for longer, rather than allowing the compound to be quickly exported or degraded. Together, these effects convert a drug that struggles to reach its target into one that arrives in force and lingers.

Higher intracellular accumulation translated into greater apoptotic activity, meaning the treated cancer cells were more likely to undergo programmed cell death, the controlled self-destruction pathway that cordycepin is known to activate in tumor cells. The study also reported more pronounced clonogenic activity effects, indicating a measurable impact on the ability of surviving cells to proliferate and form colonies. Prior work has established that cordycepin can induce apoptosis in breast cancer cells through caspase-dependent pathways, and can act independently of the estrogen receptor, which matters because MCF-7 cells are estrogen receptor positive and many breast cancers lose endocrine responsiveness over time. The nanoformulation amplifies this intrinsic apoptotic potential simply by getting more intact drug to the right place.

The new work builds on, and differentiates itself from, a growing body of research into cordycepin delivery systems. Previous studies have encapsulated cordycepin in poly(lactic-co-glycolic acid) nanoparticles with improved cytotoxicity and reduced hemotoxicity, loaded it into bovine serum albumin nanoparticles, complexed it with cyclodextrins to improve stability, and formulated CD44-targeted lipid polymer hybrid nanoparticles carrying Cordyceps militaris extracts. Liposome-encapsulated nanocordycepin has also shown enhanced activity in breast and cervical cancer cells. The present study’s contribution is to demonstrate that solid lipid nanoparticles, a simpler and arguably more clinically friendly platform given their biocompatible composition and solvent-free preparation, achieve the same essential goals: protection from adenosine deaminase, resistance to acidic degradation, sustained pH-responsive release, and greater intracellular delivery.

For now, the findings rest on in vitro evidence, and the usual caveats apply: nanoparticle behavior in cell culture does not always predict performance in living animals, where protein adsorption, immune clearance, and tumor heterogeneity complicate the picture. The authors note that their data are available upon reasonable request, and the work was supported by institutional resources at the Central University of Gujarat, JSS Academy of Higher Education and Research, and Parul University, with doctoral fellowships from the University Grants Commission. Even so, the study adds a meaningful data point to one of nanomedicine’s most persistent arguments, that the fastest route to new cancer drugs sometimes runs not through novel molecules but through smarter packaging of old ones. For a compound isolated from a parasitic fungus that has been used in Chinese and Tibetan medicine for centuries, a lipid shell a few hundred nanometers wide may be exactly what it takes to finally make the leap from promising natural product to working therapy.

Subject of Research: Solid lipid nanoparticle delivery of cordycepin for breast cancer therapy

Article Title: Overcoming cordycepin limitations with SLNs-based nanoformulation: formulation development and cytotoxicity evaluation against human breast cancer cells

Article References: Overcoming cordycepin limitations with SLNs-based nanoformulation: formulation development and cytotoxicity evaluation against human breast cancer cells. (n.d.). https://doi.org/10.1007/s12032-026-03407-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03407-2

Keywords: cordycepin, solid lipid nanoparticles, breast cancer, MCF-7 cells, nanomedicine, drug delivery, apoptosis, adenosine deaminase, cytotoxicity, natural products, chemotherapy, nanoencapsulation

The case, reported in the journal Respirology Case Reports, describes how a lethal cancer called sarcomatoid malignant pleural mesothelioma hid behind a convincing facade of infection. When thoracoscopy under local anesthesia revealed a purulent, pus-filled effusion with fibrin deposited across the pleural cavity, the medical team could not even obtain an adequate pleural biopsy because inflammation obscured the tissue. Acting on a clinically suspected diagnosis of tuberculosis pleurisy, physicians in January 2025 began empiric anti-tuberculosis therapy with the standard four-drug regimen of isoniazid, rifampicin, ethambutol, and pyrazinamide. The patient had a smoking history of 10 pack-years and had worked in administrative roles at construction sites, an occupation that can involve asbestos exposure, the primary known cause of mesothelioma. His history also included colon cancer, surgically treated at stage IIIA, adding another layer of complexity to the clinical picture.

For four months the treatment failed. The pleural effusion persisted, and a positron emission tomography scan fused with computed tomography, which uses a radioactive glucose analog to light up metabolically active tumors, showed no abnormal accumulation to suggest malignancy. By April 2025 the patient was referred to a second hospital, where surgeons performed a thoracoscopic biopsy at the site of pleural thickening identified on preoperative imaging. The histopathology was frustratingly non-specific: fibrous pleural thickening without any granulomatous inflammation, the clustered immune structures characteristic of tuberculosis, and no acid-fast bacilli visible under Ziehl-Neelsen staining. Cultures of the tissue for mycobacteria and ordinary bacteria were all negative. The biopsy, in other words, proved the absence of infection but could not name what was actually there.

What happened next provides the dramatic core of the report. Two months after the surgical biopsy, a routine follow-up CT scan in August 2025 revealed a new mass in the posterior right eighth rib, invading bone, and the patient had begun to feel pain at the site. A CT-guided percutaneous biopsy of that rapidly growing mass delivered tissue that was still ambiguous under the microscope. The specimen showed fibrosis mingled with a proliferation of atypical spindle cells, elongated cells with enlarged and irregular nuclei that could belong to either an aggressive cancer or a benign scarring process called fibrosing pleuritis. Even experienced pathologists cannot reliably separate these two entities on routine hematoxylin and eosin stained sections, and this case proved no exception.

The diagnostic breakthrough came from molecular testing rather than conventional histology. Immunohistochemistry showed that the spindle cells stained diffusely positive for CAM5.2, a cytokeratin marker that hints at epithelial origin and supports a mesothelial lineage, but the definitive answer required fluorescence in situ hybridization, or FISH. This technique uses fluorescently labeled DNA probes to examine tumor cells at the level of individual genes. In this patient, FISH revealed a homozygous deletion of the CDKN2A gene, also known as p16, meaning both copies of this critical tumor suppressor had been lost. The deletion of a gene whose normal function is to halt the cell cycle when DNA damage is detected is a hallmark of malignant transformation. Because homozygous CDKN2A loss is frequently found in sarcomatoid mesothelioma but is absent in benign fibrosing pleuritis, its detection confirmed the diagnosis of sarcomatoid mesothelioma. The disease had been masquerading as infection and inflammation for months, and molecular pathology finally unmasked it.

The clinical course then moved with brutal speed. Just two months after the definitive diagnosis, the patient died under best supportive care. That trajectory is characteristic of sarcomatoid mesothelioma, which carries a poorer prognosis and progresses more rapidly than the epithelioid and biphasic subtypes of the disease. Within the sarcomatoid family, the case authors note, lies an even more deceptive variant called desmoplastic mesothelioma, whose early lesions are pathologically indistinguishable from benign fibrous pleuritis. In this patient, retrospective analysis of the original surgical biopsy proved revelatory: when researchers later stained that older sample, scattered spindle cells turned out to be positive for CAM5.2, and FISH on the same archival tissue also detected the CDKN2A deletion. The cancer had been present all along, hiding in plain sight within a fibrotic pleura, in an occult phase where the tumor burden was too small and too metabolically quiet to register on FDG-PET or to catch the pathologist’s eye.

Why was tuberculosis such a plausible impostor? The report contextualizes the difficulty with sobering numbers. The sensitivity of pleural fluid smears for acid-fast bacilli in tuberculous pleurisy is below 10 percent, and cultures are positive in fewer than 30 percent of cases, meaning that a negative smear or culture never truly excludes the disease. Adenosine deaminase, while useful, has limited specificity, and in regions where tuberculosis remains common, clinicians are often justified in starting empiric therapy when the clinical constellation fits. Here, a positive interferon-gamma release assay combined with a lymphocyte-predominant exudate created a strong circumstantial case. Yet previous studies indicate that among patients who receive a diagnosis of non-specific pleuritis after invasive biopsy, between 5 and 15 percent are eventually found to have malignancy, particularly mesothelioma. That statistic transforms an initially reassuring non-specific biopsy result into a warning sign demanding surveillance rather than closure.

The British Thoracic Society guidelines recommend approximately 12 months of follow-up for patients whose pleural biopsies yield non-specific results, and this case illustrates precisely why such vigilance matters. When the effusion failed to resolve despite four months of antituberculosis drugs, the appropriate response was prompt, repeated pleural biopsy rather than continued ineffective treatment. The report argues that clinicians facing presumed tuberculous pleurisy that responds poorly to therapy must actively hunt for malignant mesothelioma. It also highlights a structural gap in clinical practice: FISH testing for CDKN2A deletion remains limited in availability and prevalence in general clinical settings, and restricted access to this powerful tool can delay mesothelioma diagnoses, sometimes fatally. Expanding access to molecular diagnostics for pleural disease emerges as an urgent unmet need.

Beyond its immediate clinical lessons, the case offers a window into how modern oncology resolves diagnostic uncertainty. A single molecular event, the loss of both copies of a tumor suppressor gene, served as the fingerprint that distinguished a rapidly lethal cancer from benign scar tissue that looked nearly identical under the microscope. The trajectory of this patient’s illness, from an occult phase invisible to imaging and pathology, through an explosive two-month emergence of a bone-invading chest wall mass, to death within weeks of diagnosis, underscores the aggressive biology of the sarcomatoid subtype. For physicians, the message is layered: treat the statistics with humility, because negative cultures and smears cannot exclude tuberculosis, and non-specific biopsies cannot exclude mesothelioma. For patients with unexplained pleural effusions that defy treatment, repeated biopsies and multidisciplinary discussion, combined with molecular tools capable of interrogating the genome rather than only the architecture of tissue, may be the difference between catching a cancer in time and discovering it only after it has claimed the advantage. This single case, reported with full clinical detail, adds a compelling data point to the growing argument that the future of pleural disease diagnosis lies as much in molecular pathology as in the pathologist’s optical microscope.

Subject of Research: A case report of sarcomatoid malignant pleural mesothelioma initially misdiagnosed and treated as tuberculous pleurisy

Article Title: Sarcomatoid Mesothelioma Revealed After Treatment for Tuberculous Pleurisy: A Case Report

Article References: Nagayama, D., Yokoo, K., Yabushita, Y., Sekikawa, M., Abe, M., Kato, H., Takayanagi, A., Takahashi, B., Kato‐Shinomiya, M., Ota, S., Yamada, G., Hiroshima, K., & Chiba, H. (2026). Sarcomatoid Mesothelioma Revealed After Treatment for Tuberculous Pleurisy: A Case Report. Respirology Case Reports, 14(9), Article e70734. https://doi.org/10.1002/rcr2.70734

Image Credits: AI Generated

DOI: 10.1002/rcr2.70734

Keywords: sarcomatoid mesothelioma, tuberculous pleurisy, pleural effusion, CDKN2A deletion, FISH testing, pleural biopsy, interferon-gamma release assay, adenosine deaminase, fibrosing pleuritis, immunohistochemistry, PET-CT, case report